Human recombinant soluble ACE2(hrsACE2)shows promise for treating severe COVID19

作     者：Tarek Mohamed Abd El-Aziz Ahmed Al-Sabi James D.Stockand Tarek Mohamed Abd El-Aziz;Ahmed Al-Sabi;James D.Stockand

作者机构：Department of Cellular and Integrative PhysiologyUniversity of Texas Health Science Center at San AntonioSan AntonioTX 78229-3900USA Zoology DepartmentFaculty of ScienceMinia UniversityEl-Minia 61519Egypt College of Engineering and TechnologyAmerican University of the Middle EastKuwaitKuwait 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：303-304页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 10[医学] 

基　　金：National Institute of Diabetes and Digestive and Kidney Diseases  NIDDK  (R01DK113816) 

主　　题：ACE2 al cavity 

摘      要：A recent study by Zoufaly et al.published in The Lancet Respiratory Medicine describes encouraging data from the first severe COVID-19 patient successfully treated with human recombinant soluble angiotensin-converting enzyme-2(hrsACE2).1 The published data document upon treatment of an adaptive immune response,the disappearance of the virus swiftly from the serum,the nasal cavity and lungs,and a reduction of inflammatory cytokine levels that are critical for COVID-19 pathology.Notably,the use of hrsACE2 did not impede the generation of neutralizing antibodies,leading to a significant clinical improvement of the treated patient.